Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George T Grossberg

Showing results (31-40 of 133) with videos related to

Pageof 14
Sort By:
Expert Review of Neurotherapeutics|June 14, 2016
Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeuticsWilliam James Deardorff, George T Grossberg
Expert Opinion on Investigational Drugs|December 13, 2016
AVP-786 for the treatment of agitation in dementia of the Alzheimer's typeRicardo P Garay, George T Grossberg
International Journal of Alzheimer'S Disease|September 24, 2010
Circadian rhythm disturbances in patients with Alzheimer's disease: a reviewDawit A Weldemichael, George T Grossberg
Neurology|July 5, 2005
Diagnosis and treatment of Alzheimer's diseaseAbhilash K Desai, George T Grossberg
Expert Review of Neurotherapeutics|September 16, 2005
Rivastigmine for Alzheimer's diseaseAbhilash K Desai, George T Grossberg
Expert Review of Neurotherapeutics|October 9, 2009
Buspirone in Alzheimer's diseaseAbhilash K Desai, George T Grossberg
Expert Opinion on Pharmacotherapy|June 15, 2010
Memantine ER, a once-daily formulation for the treatment of Alzheimer's diseaseNazem Bassil, Papan Thaipisuttikul, George T Grossberg
The Medical Clinics of North America|September 12, 2006
Mood disorders in the elderlyMehret Gebretsadik, Sundeep Jayaprabhu, George T Grossberg
Therapeutic Advances in Drug Safety|March 2, 2018
An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmineRita Khoury, Jayashree Rajamanickam, George T Grossberg
Expert Opinion on Emerging Drugs|March 4, 2017
Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's diseaseAmanda Calhoun, Je Ko, George T Grossberg
Pageof 14

Showing results (31-40 of 133) with videos related to

Sort By:
Pageof 14
Expert Review of Neurotherapeutics|June 14, 2016
Targeting neuroinflammation in Alzheimer's disease: evidence for NSAIDs and novel therapeuticsWilliam James Deardorff, George T Grossberg
Expert Opinion on Investigational Drugs|December 13, 2016
AVP-786 for the treatment of agitation in dementia of the Alzheimer's typeRicardo P Garay, George T Grossberg
International Journal of Alzheimer'S Disease|September 24, 2010
Circadian rhythm disturbances in patients with Alzheimer's disease: a reviewDawit A Weldemichael, George T Grossberg
Neurology|July 5, 2005
Diagnosis and treatment of Alzheimer's diseaseAbhilash K Desai, George T Grossberg
Expert Review of Neurotherapeutics|September 16, 2005
Rivastigmine for Alzheimer's diseaseAbhilash K Desai, George T Grossberg
Expert Review of Neurotherapeutics|October 9, 2009
Buspirone in Alzheimer's diseaseAbhilash K Desai, George T Grossberg
Expert Opinion on Pharmacotherapy|June 15, 2010
Memantine ER, a once-daily formulation for the treatment of Alzheimer's diseaseNazem Bassil, Papan Thaipisuttikul, George T Grossberg
The Medical Clinics of North America|September 12, 2006
Mood disorders in the elderlyMehret Gebretsadik, Sundeep Jayaprabhu, George T Grossberg
Therapeutic Advances in Drug Safety|March 2, 2018
An update on the safety of current therapies for Alzheimer's disease: focus on rivastigmineRita Khoury, Jayashree Rajamanickam, George T Grossberg
Expert Opinion on Emerging Drugs|March 4, 2017
Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer's diseaseAmanda Calhoun, Je Ko, George T Grossberg
Pageof 14